And we also had important innovation highlights, which we'll talk about a bit more over the course of the call; Kisqali's FDA approval and CHMP positive opinion in hormone receptor positive HER2 ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

KEY DRUGS: Early breast-cancer treatment Kisqali, immunology drug Cosentyx, neuroscience medicine Kesimpta and cardiovascular drug Entresto--the patent of which expires in 2025--are expected to be ...

NVS maintains strong momentum on the back of a strong and diverse portfolio with drugs like Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. With the separation of Sandoz, Novartis is ...

I expect Kisqali net sales to grow nearly 40% Y/Y to $775 million at the mid-point of the $750-$800 million range. Kisqali was recently approved to reduce the recurrence in people with HR+/HER2 ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for breast cancer, providing a boost to Novartis' (NOVN: VX) Kisqali (ribociclib). The new guidelines make ...

Novartis’ revenues in the third quarter of 2024 are likely to have been driven by key drugs like Kesimpta, Entresto, Kisqali, Cosentyx and Pluvicto. New York-based Pfizer has an Earnings ESP of ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...